Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Antibe Therapeutics Inc. has undergone significant changes, with the appointment of FTI Consulting Canada Inc. as receiver following the termination of its CCAA proceedings, and the resignation of five board members. Additionally, the company’s common shares are set to be delisted from the TSX on May 24, 2024.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.